News

The Center for Movement Disorders and Neurorestoration at the University of California (UC) Davis Health Department of Neurology will serve as a Parkinson’s Foundation Center of Excellence starting this month and for at least the next five years. The center joins a Global Care Network that’s grown…

The U.S. Food and Drug Administration (FDA) is asking for more information concerning the safety of  IPX203, an extended-release oral formulation of carbidopa and levodopa, before a final approval decision in treating Parkinson’s disease symptoms can be made. In a complete response letter to Amneal Pharmaceuticals,…

Researchers have created a system that could be developed to allow at-home measuring of levodopa levels in people with Parkinson’s disease. The system was described in the study “Smartphone-based detection of levodopa in human sweat using 3D printed sensors,” published in Analytica Chimica Acta.

An algorithm can accurately identify people who are at increased risk of developing Parkinson’s-like motor problems in coming years, a new study shows. The study, “The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson’s Disease,” was published in Movement Disorders. The…

The early appearance of minor hallucinations in people with Parkinson’s disease might be a predictor of faster cognitive decline, a recent study suggests. Among those with hallucinations, cognitive decline was also associated with electrical activity in the frontal lobe, a part of the brain that controls cognition. The study,…

Changes in vision and eye health prior to deep brain stimulation (DBS) surgery can be a significant predictor of delirium in the hours after this Parkinson’s disease surgery, a study suggests. A post-operative risk of the psychiatric condition was found to be greater in older patients and those with…

Treatment with bemdaneprocel (BRT-DA01), BlueRock Therapeutics’s investigational cell-based therapy, was safe and well tolerated among patients with advanced-stage Parkinson’s disease, according to top-line results from a Phase 1 clinical trial. Furthermore, data also showed that transplantation was feasible, and there was evidence of cell survival and engraftment in…

The Parkinson’s Foundation has expanded its Global Care Network by adding four Centers of Excellence and four Comprehensive Care Centers to increase access to specialized multidisciplinary care for people with Parkinson’s disease. This expansion recognizes centers within a broad geographic region, including the first-ever designations in Wisconsin,…

Researchers have uncovered new evidence that activity in the gut can directly influence brain function, a relationship that’s been proposed to contribute to Parkinson’s disease. Using specialized fibers with the ability to stimulate nerve cells with light, called optogenetics, the scientists found that by altering cell activity in the…

Freeline Therapeutics announced plans to leverage knowledge gained from its FLT201 gene therapy program in Gaucher disease to advance a similar candidate to treat people whose Parkinson’s is tied to mutations in the GBA1 gene. “Our GBA1-linked Parkinson’s disease program is a natural extension of our…